▎WuXiEdited by Kant Content Team
Acepodia, Inc. today announced a strategic clinical collaboration with Pfizer Ignite, a subsidiary of Pfizer.Jointly support the development of its investigational therapies in the field of autoimmune diseases.Pfizer Ignite leverages Pfizer's extensive resources, scale, and expertise, as well as its successful experience in breakthrough drug development, to help biotechnology companies accelerate the innovation process from preclinical R&D through the entire development lifecycle.Under this agreement, Pfizer Ignite will provide strategic guidance and resource support to Acepodia, aiding in the development of potential “first-in-class” cell therapies for cancer and autoimmune diseases.
Acepodia’s Antibody Cell Conjugate (ACC) platform utilizes bioorthogonal chemistry, building on the groundbreaking work of 2022 Nobel laureate Dr. Carolyn Bertozzi in applying click chemistry to living systems, to create an off-the-shelf CAR-T cell therapy that does not require genetic engineering.This therapy is more suitable for scalable production and avoids common side effects of CAR-T cell therapy, such as cytokine release syndrome and neurotoxicity.Acepodia's first clinical-stage candidate drug, ACE1831, is an off-the-shelf γδ2 T cell therapy targeting CD20.It is currently in Phase 1 human clinical trials for patients with non-Hodgkin lymphoma and has demonstrated potent and durable effects after a single treatment at the lowest dose.
▲Acepodia's R&D Pipeline (Source: Acepodia's Official Website)
Through collaboration with Pfizer Ignite, Acepodia will benefit from Pfizer's resources, deep expertise, and R&D capabilities, covering multiple stages from clinical trial design to regulatory strategies, optimizing the development process of innovative drugs.
▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
[1] Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases. Retrieved September 4, 2024, from https://www.prnewswire.com/news-releases/acepodia-enters-strategic-clinical-collaboration-with-pfizer-to-accelerate-development-of-antibody-cell-conjugation-based-cell-therapies-in-autoimmune-diseases-302236377.htmlDisclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In View, Focusing on Global Biomedical Health Innovation
